Nxera Pharma Defends Core IP Amidst Profitability Turnaround
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
Healthcare
Page 22- May 07, 2026 · 17:55 · VHI · Routine +01
Q1 Revenue Surges 47%
VitalHub Reports First Quarter 2026 Results
- May 07, 2026 · 17:24 · EXE · Material +02
Extendicare’s Investment-Grade Debut and CBI Close Cement a Transformative Growth Trajectory
Extendicare Announces 2026 First Quarter Results
- May 07, 2026 · 17:00 · NLH · Routine +03
Nova Leap’s Q1 shines with record TTM revenue and a bolt-on Nova Scotia acquisition, but the small-cap story still needs to prove scalability beyond the home.
Nova Leap Health Corp. Posts Q1 2026 Results
- May 07, 2026 · 17:00 · CPH · Routine +04
Cipher Goes Debt-Free and Boasts $71M in Dry Powder, But Stagnant Sales Raise the Bar for Deal-Driven Growth
Cipher Pharmaceuticals Reports First Quarter Results
- May 07, 2026 · 16:05 · PRN · Material +05
Humana coverage and surging procedure volumes push TULSA-PRO toward standard of care, but path to profitability still requires execution.
Profound Medical Reports Strong First Quarter 2026 Financial Results
- May 07, 2026 · 16:01 · WELL · Routine +06
WELL Health Q1 Earnings Beat Revenue Targets But Cash Flow Divergence Raises Liquidity Concerns
WELL Health Delivers Record Q1-2026 with Canadian Clinics Run Rate Exceeding $500M and Revenue Up 25% to $368M
- May 07, 2026 · 07:31 · BPC · Routine +07
Peptide Patch Progress Tests Investor Patience Amid Capital Burn
The Precision Peptide Company Nears Commercial Launch of Needle-Free BPC-157 Patch as Final Testing Advances
- May 07, 2026 · 07:30 · BCT · Routine +08
BriaCell Therapeutics Corp
BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
- May 07, 2026 · 07:30 · UDOC · Routine +09
Legacy Asset Relaunch Fails to Halt Dilution-Driven Decline in Rural eHealth Play
UniDoc to Update and Relaunch Legacy eHealth Systems with Pawnee Mental Health Services Across Rural Kansas
- May 07, 2026 · 07:27 · CRDL · Routine +10
Cardiol Therapeutics Validates Pilot Data Amidst Pivotal Trial Progress, Yet Market Remains Cautious on Phase III Readout
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
- May 07, 2026 · 07:25 · KNE · Routine −11
Kane Biotech Seeks $1M Amidst Revenue Slump and Cash Burn Concerns
Kane Biotech Announces New Private Placement Offering
- May 07, 2026 · 07:15 · ASG · Routine +12
Patent Milestone Masks Cash Strain and Debt Overhang Despite EBITDAC Turnaround
Aurora Spine Announces Issuance of Fourth U.S. Patent Covering DEXA Technology(TM) Bone Density-Matched Implants
- May 07, 2026 · 07:00 · BLCO · Routine +13
Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise
Bausch + Lomb Launches Bi-Blade+(TM) Dual-Port Vitrectomy Cutter in Europe
- May 07, 2026 · 07:00 · QNTM · Routine +14
Quantum BioPharma Extends Runway on Crypto Gains as Lucid-MS Enters Phase 2
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026